Replimmune shares are trading lower after the company announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for the treatment of locally advanced or metastatic CSCC and provided initial data for all patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.
Portfolio Pulse from Benzinga Newsdesk
Replimmune's stock is trading lower following the announcement of results from the CERPASS trial of RP1 with cemiplimab in treating advanced CSCC, and initial data from the IGNYTE trial's anti-PD1 failed melanoma cohort.
December 05, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Replimmune's shares are down after the company released results from its CERPASS trial and initial melanoma data from the IGNYTE trial.
The negative market reaction is likely due to investors being unimpressed with the CERPASS trial results and the initial melanoma data, which could raise concerns about the efficacy of RP1 and its future revenue potential.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100